Examples of 'reduced immunogenicity' in a sentence
Meaning of "reduced immunogenicity"
reduced immunogenicity ~ decreased ability of a substance to provoke an immune response in the body
How to use "reduced immunogenicity" in a sentence
Basic
Advanced
reduced immunogenicity
They have reduced immunogenicity when applied in vivo.
Pseudomonas exotoxin a with reduced immunogenicity.
It has a reduced immunogenicity compared with CRM197 and with DTR WT.
These approaches have produced antibodies having reduced immunogenicity.
They have no or reduced immunogenicity when applied in vivo.
Another embodiment is a pegylated form of AvPAL variant with reduced immunogenicity.
They also have reduced immunogenicity.
Engineered polypeptides having enhanced duration of action and reduced immunogenicity.
Another way of producing antibodies with reduced immunogenicity is the deimmunization of antibodies.
One embodiment is a pegylated form of NpPAL variant with reduced immunogenicity.
Pegylated PAL variants with reduced immunogenicity are provided herein.
One example is a pegylated form of NpPAL variant with reduced immunogenicity.
Pegylated PAL variants with reduced immunogenicity are disclosed herein.
Using heparin or heparin analogs is preferred because there appears to be reduced immunogenicity.
These studies confirm the reduced immunogenicity of RNA molecules of the present invention.
See also
The invention provides a pegylated form of AvPAL variant with reduced immunogenicity.
Such human Mabs have significantly reduced immunogenicity when therapeutically administered to humans.
All four of these properties result in a protein having considerably reduced immunogenicity.
Further potential advantages include reduced immunogenicity of the therapeutic compound, and lower toxicity.
According to the invention such a light chain would lead to an antibody with reduced immunogenicity.
Therapeutic protein compositions having reduced immunogenicity and / or improved efficacy.
Methods and compositions of the invention also provide albumin fusión proteins with reduced immunogenicity.
The resulting mouse-human chimeric antibody should have reduced immunogenicity and improved pharmacokinetics in humans.
In some embodiments, polypeptide sequences of the invention are not immunogenic and / or have reduced immunogenicity.
Serological results indicated reduced immunogenicity of collagen-PEG vs. ZCI.
Normally, reduced antibody reactivity will be an indication of reduced immunogenicity.
HVH-6M and hVH-6L exhibit reduced immunogenicity relative to their respective parental polypeptides.
They can also be used as a milk solids replacement where achieving reduced immunogenicity is desirable.
Reduced immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules is demonstrated herein ( Examples 1-8 ).
Despite this in monkeys and patients greatly reduced immunogenicity has been reported.
If non-human preparations are desired, they can be prepared to have reduced immunogenicity.
A “ modified deleted protein ” may also have reduced immunogenicity or antigenicity.
These mAbs retain their specificity and binding affinity, but show reduced immunogenicity.
In some embodiments of the present invention, such reduced immunogenicity may be advantageous.
These modifications are made to further refine antibody performance, specificity, affinity and reduced immunogenicity.
Chimeric antibodies with improved Fc effector functions and reduced immunogenicity will also be explored.
Thus, the invention also provides methods for producing fusión proteins with reduced immunogenicity.
Coagulation factor VIII with reduced immunogenicity.
Construction, expression, and heterodimerization properties of SEED molecules with reduced immunogenicity.
The polypeptide of formula ( I ) has a reduced immunogenicity in human.
Another embodiment is a pegylated form of Nostoc punctiforme PAL ( NpPAL ) variant with reduced immunogenicity.
Figure 15a shows results of a cell-surface binding assay of reduced immunogenicity 4G7 variants to Raji cells.
The present invention relates to improved Pseudomonas exotoxin A ( " PE " ) with reduced immunogenicity.
Anti-CD19 antibodies with reduced immunogenicity.
The present invention provides improved Pseudomonas exotoxin A ( “ PE ” ) with reduced immunogenicity.
Thus in a preferred embodiment, the cells have been selected for a reduced immunogenicity in the recipient.
In another aspect, selection of non-surface antibody mutations allows for reduced immunogenicity risk.
In one embodiment, pegylated prokaryotic PAL variants with reduced immunogenicity are provided.
In another aspect, selection of non-surface protein mutations allows for reduced immunogenicity risk.
Even elimination of one T cell epitope results in reduced immunogenicity.
You'll also be interested in:
Examples of using Immunogenicity
Show more
Immunogenicity in adults treated with intravenous abatacept
Key considerations on potential immunogenicity of biological medicines
Immunogenicity in adults treated with subcutaneous abatacept
Examples of using Reduced
Show more
The original should be reduced as little as possible
Reduced throughput time from production to delivery
Border delays must be reduced as much as possible
